A British biotech company will pay University of Massachusetts Medical School a milestone payment as a result of a U.S. patent received in conjunction with the Carnegie Institution.
The medical school and Carnegie signed a license agreement in 2008 with Oxford BioMedica for the right to RNA interference (RNAi) technology developed by Nobel laureate Craig Mello at UMass and Andrew Z. Fire at Carnegie.
The technology uses RNAi to inhibit the expression of a target gene in animal cells, including mammalian cells. The patent covers the delivery of RNAi using "lentiviral" vectors, which deliver genetic information efficiently and without toxicity, according to BioMedica.
The amount of the milestone payment was not disclosed.